EPHA2 and lung carcinoma: Therefore, we finally explored the role of the RSK–EphA2 pathway in patients' prognosis using a lung cancer tissue microarray, which consists of a total of 353 samples, including 175 adenocarcinomas, 88 squamous cell carcinomas and others.